Novartis AG
USE OF IL-1B BINDING ANTIBODIES FOR THE TREATMENT OF ALCOHOLIC HEPATITIS
Last updated:
Abstract:
The present invention relates to a method for treating or alleviating the symptoms of alcoholic hepatitis in a subject, comprising administering gevokizumab or 2-5 mg of canakinumab per kg of body weight to a subject in need thereof.
Status:
Application
Type:
Utility
Filling date:
16 Jun 2021
Issue date:
7 Oct 2021